Nowak-Markwitz Ewa
Klinika Ginekologii Onkologicznej Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu.
Ginekol Pol. 2009 Aug;80(8):615-9.
Ovarian cancer treatment after cytoreductive surgery is based solely on chemotherapy. Pegylated liposomal doxorubicin (PLD) is a cytotoxic agent of verified efficacy in the treatment of ovarian cancer and is may be used in the first and the following lines of chemotherapy. In the first-line ovarian cancer treatment the combination of PLD with carboplatin assures a prolonged interval to progression and produces less toxicity when compared to carboplatin with paclitaxel schedule. Calypso trial has also revealed that in platinum-sensitive recurrent ovarian cancer PLD with carboplatin shows better anticancer efficiency in comparison to combination carboplatin with paclitaxel and its toxicity profile is quite unique. Namely PLD does not cause hematological complications, neuropathy balding and hair loss that are characteristic of other chemotherapeutics applied in ovarian cancer treatment. Palmar-plantar erythrodysesthesia, a typical and commonly noted adverse event, rarely occurs when the dosage is 40 mg/m2 iv. Thus, PLD ought to be the drug of choice in recurrent ovarian cancer treatment, both platinum-sensitive and platinum-insensitive one. In case of partially platinum-sensitive ovarian cancer PLD allows for a longer without-platinum period what in turn allows for yet another treatment with platinum, and helps achieve a prolonged interval to progression and progression-free survival time.
肿瘤细胞减灭术后的卵巢癌治疗仅基于化疗。聚乙二醇化脂质体阿霉素（PLD）是一种经证实对卵巢癌治疗有效的细胞毒性药物，可用于一线及后续化疗。在一线卵巢癌治疗中，PLD与卡铂联合使用可确保延长疾病进展间隔时间，与卡铂联合紫杉醇方案相比，毒性更小。Calypso试验还表明，在铂敏感的复发性卵巢癌中，PLD与卡铂联合使用比卡铂联合紫杉醇显示出更好的抗癌效果，其毒性特征相当独特。也就是说，PLD不会引起血液学并发症、神经病变、脱发等卵巢癌治疗中其他化疗药物特有的不良反应。手足红斑感觉异常是一种典型且常见的不良事件，当静脉注射剂量为40mg/m²时很少发生。因此，PLD应该是复发性卵巢癌治疗的首选药物，无论是铂敏感还是铂耐药的复发性卵巢癌。对于部分铂敏感的卵巢癌，PLD可延长无铂治疗期，进而可再次使用铂类药物治疗，并有助于延长疾病进展间隔时间和无进展生存期。
